459 related articles for article (PubMed ID: 28650456)
1. A tripartite complex of suPAR, APOL1 risk variants and α
Hayek SS; Koh KH; Grams ME; Wei C; Ko YA; Li J; Samelko B; Lee H; Dande RR; Lee HW; Hahm E; Peev V; Tracy M; Tardi NJ; Gupta V; Altintas MM; Garborcauskas G; Stojanovic N; Winkler CA; Lipkowitz MS; Tin A; Inker LA; Levey AS; Zeier M; Freedman BI; Kopp JB; Skorecki K; Coresh J; Quyyumi AA; Sever S; Reiser J
Nat Med; 2017 Aug; 23(8):945-953. PubMed ID: 28650456
[TBL] [Abstract][Full Text] [Related]
2. Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD.
Luo S; Coresh J; Tin A; Rebholz CM; Chen TK; Hayek SS; Tracy M; Lipkowitz MS; Appel LJ; Levey AS; Inker LA; Reiser J; Grams ME
Clin J Am Soc Nephrol; 2018 Jul; 13(7):1013-1021. PubMed ID: 29903900
[TBL] [Abstract][Full Text] [Related]
3. APOL1 Genotype and Glomerular and Tubular Kidney Injury in Women With HIV.
Jotwani V; Shlipak MG; Scherzer R; Parekh RS; Kao WH; Bennett M; Cohen MH; Nowicki M; Sharma A; Young M; Tien PC; Parikh CR; Estrella MM
Am J Kidney Dis; 2015 Jun; 65(6):889-98. PubMed ID: 25921719
[TBL] [Abstract][Full Text] [Related]
4. APOL1 genetic variants, chronic kidney diseases and hypertension in mixed ancestry South Africans.
Matsha TE; Kengne AP; Masconi KL; Yako YY; Erasmus RT
BMC Genet; 2015 Jun; 16():69. PubMed ID: 26112018
[TBL] [Abstract][Full Text] [Related]
5. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.
Beckerman P; Bi-Karchin J; Park AS; Qiu C; Dummer PD; Soomro I; Boustany-Kari CM; Pullen SS; Miner JH; Hu CA; Rohacs T; Inoue K; Ishibe S; Saleem MA; Palmer MB; Cuervo AM; Kopp JB; Susztak K
Nat Med; 2017 Apr; 23(4):429-438. PubMed ID: 28218918
[TBL] [Abstract][Full Text] [Related]
6. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.
Lan X; Jhaveri A; Cheng K; Wen H; Saleem MA; Mathieson PW; Mikulak J; Aviram S; Malhotra A; Skorecki K; Singhal PC
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F326-36. PubMed ID: 24899058
[TBL] [Abstract][Full Text] [Related]
7. suPAR and chronic kidney disease-a podocyte story.
Zeier M; Reiser J
Pflugers Arch; 2017 Aug; 469(7-8):1017-1020. PubMed ID: 28689240
[TBL] [Abstract][Full Text] [Related]
8. Plasma apolipoprotein L1 levels do not correlate with CKD.
Bruggeman LA; O'Toole JF; Ross MD; Madhavan SM; Smurzynski M; Wu K; Bosch RJ; Gupta S; Pollak MR; Sedor JR; Kalayjian RC
J Am Soc Nephrol; 2014 Mar; 25(3):634-44. PubMed ID: 24231663
[TBL] [Abstract][Full Text] [Related]
9. APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.
Gutiérrez OM; Judd SE; Irvin MR; Zhi D; Limdi N; Palmer ND; Rich SS; Sale MM; Freedman BI
Nephrol Dial Transplant; 2016 Apr; 31(4):602-8. PubMed ID: 26152403
[TBL] [Abstract][Full Text] [Related]
10. Re-Sequencing of the APOL1-APOL4 and MYH9 Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression.
Hawkins GA; Friedman DJ; Lu L; McWilliams DR; Chou JW; Sajuthi S; Divers J; Parekh RS; Li M; Genovese G; Pollack MR; Hicks PJ; Bowden DW; Ma L; Freedman BI; Langefeld CD
Am J Nephrol; 2015; 42(2):99-106. PubMed ID: 26343748
[TBL] [Abstract][Full Text] [Related]
11. Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression.
Chen TK; Choi MJ; Kao WH; Astor BC; Scialla JJ; Appel LJ; Li L; Lipkowitz MS; Wolf M; Parekh RS; Winkler CA; Estrella MM; Crews DC
Clin J Am Soc Nephrol; 2015 Dec; 10(12):2128-35. PubMed ID: 26430087
[TBL] [Abstract][Full Text] [Related]
12. APOL1 risk variants, race, and progression of chronic kidney disease.
Parsa A; Kao WH; Xie D; Astor BC; Li M; Hsu CY; Feldman HI; Parekh RS; Kusek JW; Greene TH; Fink JC; Anderson AH; Choi MJ; Wright JT; Lash JP; Freedman BI; Ojo A; Winkler CA; Raj DS; Kopp JB; He J; Jensvold NG; Tao K; Lipkowitz MS; Appel LJ; ;
N Engl J Med; 2013 Dec; 369(23):2183-96. PubMed ID: 24206458
[TBL] [Abstract][Full Text] [Related]
13. APOL1 risk alleles among individuals with CKD in Northern Tanzania: A pilot study.
Stanifer JW; Karia F; Maro V; Kilonzo K; Qin X; Patel UD; Hauser ER
PLoS One; 2017; 12(7):e0181811. PubMed ID: 28732083
[TBL] [Abstract][Full Text] [Related]
14. Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1.
Khatua AK; Cheatham AM; Kruzel ED; Singhal PC; Skorecki K; Popik W
Am J Physiol Cell Physiol; 2015 Jul; 309(1):C22-37. PubMed ID: 25924622
[TBL] [Abstract][Full Text] [Related]
15. APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease.
Tzur S; Rosset S; Skorecki K; Wasser WG
Nephrol Dial Transplant; 2012 Apr; 27(4):1498-505. PubMed ID: 22357707
[TBL] [Abstract][Full Text] [Related]
16. Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.
Alfano M; Cinque P; Giusti G; Proietti S; Nebuloni M; Danese S; D'Alessio S; Genua M; Portale F; Lo Porto M; Singhal PC; Rastaldi MP; Saleem MA; Mavilio D; Mikulak J
Sci Rep; 2015 Sep; 5():13647. PubMed ID: 26380915
[TBL] [Abstract][Full Text] [Related]
17. Combined Effects of GSTM1 Null Allele and APOL1 Renal Risk Alleles in CKD Progression in the African American Study of Kidney Disease and Hypertension Trial.
Bodonyi-Kovacs G; Ma JZ; Chang J; Lipkowitz MS; Kopp JB; Winkler CA; Le TH
J Am Soc Nephrol; 2016 Oct; 27(10):3140-3152. PubMed ID: 26940095
[TBL] [Abstract][Full Text] [Related]
18. Population-based risk assessment of APOL1 on renal disease.
Friedman DJ; Kozlitina J; Genovese G; Jog P; Pollak MR
J Am Soc Nephrol; 2011 Nov; 22(11):2098-105. PubMed ID: 21997396
[TBL] [Abstract][Full Text] [Related]
19. APOL1 variants associate with increased risk of CKD among African Americans.
Foster MC; Coresh J; Fornage M; Astor BC; Grams M; Franceschini N; Boerwinkle E; Parekh RS; Kao WH
J Am Soc Nephrol; 2013 Sep; 24(9):1484-91. PubMed ID: 23766536
[TBL] [Abstract][Full Text] [Related]
20. Impact of APOL1 polymorphism and IL-1β priming in the entry and persistence of HIV-1 in human podocytes.
Mikulak J; Oriolo F; Portale F; Tentorio P; Lan X; Saleem MA; Skorecki K; Singhal PC; Mavilio D
Retrovirology; 2016 Sep; 13(1):63. PubMed ID: 27599995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
